Serum antibodies to Onchocerca volvulus native sodium duodecylsulphate slat extracted antigens and epitopes recognized by three monoclonal antibodies designated Cam8, Cam22, and Cam28 were measured using indirect (sandwich) and competitive enzyme-linked immunosorbent assay (ELISA). Paired serum samples (n=32) were obtained before and two months post-ivermectin treatment. Those with increases of ten percent and above (≥ ≥ ≥ ≥10%) were 16 (50%) for IgG, 13 (40.7%) for both IgG1 and IgG4. Nine (28.2%) for IgM, eight (25%) for IgG3, IgA with four (12.5%) was the least, while IgG2 was not assayed due to cross-reaction. The higher increases in IgG, IgG1 and IgG4 antibodies in females (n=16) than males (n=16) were significant by T-test of unpaired data (P<0.05). Those without onchocercal skin disease, OSD (n=18) had a significant increase of 20.5± ± ± ±29.6%, with pre-and posttreatment values of 0.59± ± ± ±0.15 versus 0.68± ± ± ±0.13 for IgG antibody (P<0.05). Both IgG1 and IgG4 antibodies for those with OSD (n=14) increased by 16.0± ± ± ±24.8%. Only IgG4 antibody increased with the presence of palpable nodule and higher skin microfilarial density. Trend exhibited by Cam 22 and Cam 8 were similar to that of IgG and IgG4, respectively. In conclusion, while IgG1 and IgG4 were both associated with skin diseases, IgG4 assay proved more suitable for onchocerciasis drug screening.
INTRODUCTION

Materials and methods
Sample population
After explaining to the participant in their dialect through an interpreter from 
Assay control
Optimum concentration of antigens, serum, monoclonal antibodies, and conjugates were determined in a series of pre-titration experiments. The final assays were performed in duplicate.
Percentage inhibition was based on the difference between individuals mean OD-value and mean±2SD of the 16 internal control blank wells.
Statistical analyses
The means and standard deviation (mean±SD) for absolute and percentage changes over pretreatment values for group or subgroup were tabulated. The differences between pre-treatment and post-treatment values were subjected to t-test of paired and unpaired data. 
RESULTS
Changes in ELISA antibodies after treatment
IgG4
Pre-dose nodule -ve (n=16) 0.59± ± ± ±0.17 0.41± ± ± ±0.13 0.46± ± ± ±0.09
Post-dose 0.65± ± ± ±0.16 0.42± ± ± ±0.11 0.49± ± ± ±0.09
Percentage change 13.8± ± ± ±32.3 10.3± ± ± ±28 7.3± ± ± ±12.4
Pre-dose nodule +ve (n=16) 0.62± ± ± ±0.12 0.43± ± ± ±0.10 0.46± ± ± ±0.09
Post-dose 0.70± ± ± ±0.11 0.48± ± ± ±0.10 0.52± ± ± ±0.04
Percentage changes 16.0± ± ± ±14.1* 11.5± ± ± ±15.2 18.1± ± ± ±32.8* Note: * Intra differences in antibody levels were statistically significant (P<0.05) by t-test of paired data. The -ve = negative and +ve = positive subgroups Changes in antibodies after treatment analyzed by presence of onchocercal skin diseases.
Mean± ± ± ±SD IgG
IgG1
IgG4
Without OSD (n=18) Before treatment 0.59 ± ± ± ± 0.15 0.41 ± ± ± ± 0.11 0.47 ± ± ± ± 0.07
After treatment 0.67 ± ± ± ± 0.12 0.43 ± ± ± ± 0.11 0.50 ± ± ± ± 0.06 % changes 20.5 ± ± ± ± 29.6 * 7.0 ± ± ± ± 19.7 8.0 ± ± ± ± 11.4
With OSD (n=14) Before treatment 0.63 ± ± ± ± 0.14 0.43 ± ± ± ± 0.12 0.45 ± ± ± ± 0.10 After treatment 0.68 ± ± ± ± 0.16 0.47 ± ± ± ± 0.10 0.50 ± ± ± ± 0.08 % changes 7.7 ± ± ± ± 13.9 16.0 ± ± ± ± 24.8* 18.8 ± ± ± ± 35.4* Note: OSD= Onchocercal skin diseases. *The intra differences were statistically significant (P<0.05) by t-test of paired data.
Discussion
Antibodies to O. vulvulus adult worm extract were quantified in ELISA in same patients' (n=32) paired sera taken before and two months after initial ivermectin dosing.
Appreciable increase in antibody levels that were observed in some and not in others induced by IgE and preventing microfilaria clearance as well (7, 16, 17 & 18) . Earlier work by Whitworth et al., (19) showed there was no reduction in In addition, the studies showed there was selective unresponsiveness to antigenic epitopes defined by the mAbs.
In future, this type of study will become difficult to carry out, since most endemic areas would have been covered by the on-going community directed treatment of onchocerciasis with ivermectin.
